Landos Biopharma, Inc.
LABP · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Market Cap | $134 | $23 | $24 | $26 |
| - Cash | $29 | $38 | $42 | $44 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $105 | -$15 | -$18 | -$18 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$9 | -$6 | -$5 | -$4 |
| % Margin | – | – | – | – |
| Net Income | -$9 | -$6 | -$6 | -$4 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.43 | -0.99 | -0.94 | -0.63 |
| % Growth | -44.4% | -5.3% | -49.2% | – |
| Operating Cash Flow | -$8 | -$5 | -$2 | -$5 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$8 | -$5 | -$2 | -$5 |